Testing effectiveness (Phase 2)Looking for participantsNCT05950139
What this trial is testing
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
Who this might be right for
NSCLC Stage IVALK Fusion Protein Expression
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 12